JP5305921B2 - フィラグリン - Google Patents

フィラグリン Download PDF

Info

Publication number
JP5305921B2
JP5305921B2 JP2008545095A JP2008545095A JP5305921B2 JP 5305921 B2 JP5305921 B2 JP 5305921B2 JP 2008545095 A JP2008545095 A JP 2008545095A JP 2008545095 A JP2008545095 A JP 2008545095A JP 5305921 B2 JP5305921 B2 JP 5305921B2
Authority
JP
Japan
Prior art keywords
repeat
filaggrin
flg
mutation
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008545095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523411A (ja
JP2009523411A5 (enExample
Inventor
ウィリアム ヘンリー アーウィン マクリーン
フランシス ジェイン ドロシー スミス
Original Assignee
ザ ユニヴァーシティー コート オブ ザ ユニヴァーシティー オブ ダンディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニヴァーシティー コート オブ ザ ユニヴァーシティー オブ ダンディー filed Critical ザ ユニヴァーシティー コート オブ ザ ユニヴァーシティー オブ ダンディー
Publication of JP2009523411A publication Critical patent/JP2009523411A/ja
Publication of JP2009523411A5 publication Critical patent/JP2009523411A5/ja
Application granted granted Critical
Publication of JP5305921B2 publication Critical patent/JP5305921B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
JP2008545095A 2005-12-15 2006-12-15 フィラグリン Expired - Fee Related JP5305921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0525492.5A GB0525492D0 (en) 2005-12-15 2005-12-15 Filaggrin
GB0525492.5 2005-12-15
PCT/GB2006/004707 WO2007068946A2 (en) 2005-12-15 2006-12-15 Identification of loss-of-function mutations in filaggrin causing ichthyosis vulgaris and predisposing to other diseases

Publications (3)

Publication Number Publication Date
JP2009523411A JP2009523411A (ja) 2009-06-25
JP2009523411A5 JP2009523411A5 (enExample) 2010-02-12
JP5305921B2 true JP5305921B2 (ja) 2013-10-02

Family

ID=35736147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545095A Expired - Fee Related JP5305921B2 (ja) 2005-12-15 2006-12-15 フィラグリン

Country Status (5)

Country Link
US (1) US8999635B2 (enExample)
EP (1) EP1960539B1 (enExample)
JP (1) JP5305921B2 (enExample)
GB (2) GB0525492D0 (enExample)
WO (1) WO2007068946A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600948D0 (en) 2006-01-18 2006-02-22 Univ Dundee Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders
US20100322860A1 (en) * 2007-06-28 2010-12-23 Peter Jacobus Caspers Method for determination of a potential mutation
EP2322656A1 (en) * 2009-11-17 2011-05-18 Centre National de la Recherche Scientifique (C.N.R.S) Methods for diagnosing skin diseases
AU2010321784B2 (en) 2009-11-23 2014-04-24 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
JP5771123B2 (ja) * 2011-11-09 2015-08-26 株式会社 資生堂 プロフィラグリンｃ末端ドメイン特異的抗体及びその用途
GB201222881D0 (en) * 2012-12-19 2013-01-30 Univ Dundee Animal model
JP5943945B2 (ja) * 2014-01-29 2016-07-05 株式会社 資生堂 プロフィラグリンｃ末端ドメイン特異的抗体及びその用途
JP6803113B2 (ja) * 2016-07-01 2020-12-23 共栄化学工業株式会社 評価方法及び皮膚外用剤
RU2673804C1 (ru) * 2018-01-25 2018-11-30 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ НАУЧНОЕ УЧРЕЖДЕНИЕ "ФЕДЕРАЛЬНЫЙ ИССЛЕДОВАТЕЛЬСКИЙ ЦЕНТР ИНСТИТУТ ЦИТОЛОГИИ И ГЕНЕТИКИ СИБИРСКОГО ОТДЕЛЕНИЯ РОССИЙСКОЙ АКАДЕМИИ НАУК" (ИЦиГ СО РАН) Способ выявления мутаций 2282del4, R501X, R2447X в гене филаггрина (FLG) при вульгарном ихтиозе и атопическом дерматите
WO2019195714A1 (en) * 2018-04-05 2019-10-10 Azitra Inc Methods and compositions for treating skin disease with recombinant microorganisms
WO2020076770A1 (en) * 2018-10-08 2020-04-16 Yale University Selective binding and aggregation of human keratin in the skin barrier using human filaggrin subdomains sd67 and sd150
CN113092768A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液角蛋白,ii型细胞骨架1及其多肽片段在过敏性疾病中的应用
CN116874576B (zh) * 2023-06-28 2024-03-12 胡荣洋 一种重组人源化丝聚蛋白及其制备方法和应用
CN118460707B (zh) * 2024-07-15 2024-09-17 山东大学 检测寻常鱼鳞病相关flg基因突变的引物组、试剂盒及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512939A (ja) * 1997-11-28 2002-05-08 イノジェネティックス・ナムローゼ・フェンノートシャップ 診断および治療のためのツールとしての、リューマチ性関節炎の血清により認識されるシトルリン含有合成ペプチド
US6143502A (en) * 1999-03-31 2000-11-07 University Of Utah Research Foundation Dual-luciferase reporter system
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
GB0111324D0 (en) * 2001-05-09 2001-07-04 Unilever Plc Ambient stable beverage
EP1402889A1 (en) * 2001-06-13 2004-03-31 Masayuki Arakawa Remedies for diseases caused by nonsense mutation
EP1543157A4 (en) 2002-07-24 2006-11-15 Ptc Therapeutics Inc METHODS FOR IDENTIFYING SMALL MOLECULES MODULATING PREMATURE TRANSLATION TERMINATION AND DEGRADATION OF INDUCED MRNA BY NON-SENSE MUTATION
FI20031927A0 (fi) 2003-12-31 2003-12-31 Faron Pharmaceuticals Oy Terapeuttisesti vaikuttavia aineita ja niiden käyttö
GB0600948D0 (en) 2006-01-18 2006-02-22 Univ Dundee Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders

Also Published As

Publication number Publication date
GB0812834D0 (en) 2008-08-20
US8999635B2 (en) 2015-04-07
JP2009523411A (ja) 2009-06-25
WO2007068946A2 (en) 2007-06-21
GB2447202A (en) 2008-09-03
US20100017896A1 (en) 2010-01-21
WO2007068946A3 (en) 2007-12-21
EP1960539A2 (en) 2008-08-27
GB0525492D0 (en) 2006-01-25
EP1960539B1 (en) 2012-09-19

Similar Documents

Publication Publication Date Title
Nomura et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis
Brown et al. Atopic eczema and the filaggrin story
JP5305921B2 (ja) フィラグリン
Duchemin et al. The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency
JP5817038B2 (ja) 尿酸トランスポーター、並びに、尿酸輸送関連疾患素因及び炎症関連疾患素因の評価方法及び評価キット、検査体及び薬
Sproule et al. Molecular identification of collagen 17a1 as a major genetic modifier of laminin gamma 2 mutation-induced junctional epidermolysis bullosa in mice
Dussoix et al. Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters
CA2569083A1 (en) Detecting disease association with aberrant glycogen synthase kinase 3.beta. expression
US20100167285A1 (en) Methods and agents for evaluating inflammatory bowel disease, and targets for treatment
JP5695719B2 (ja) ジュベール症候群に関連するｃｃ２ｄ２ａ遺伝子変異及びその同定診断法
TW200934877A (en) Use of CLEC1B for the determination of cardiovascular and thrombotic risk
Singh et al. Multi-exon out of frame deletion of the FBN1 gene leading to a severe juvenile onset cardiovascular phenotype in Marfan syndrome
EP3212811A1 (en) Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
EP2411534B1 (en) Method for diagnosing or predicting a non syndromic autosomal recessive optic atrophy, or a risk of a non syndromic autosomal recessive optic atrophy.
PT1819833E (pt) Variante genética do gene de anexina a5
JP2006526986A (ja) 炎症性大腸炎の診断方法
Kowalska et al. Beta-defensin 1 gene polymorphisms at 5’untranslated region are not associated with a susceptibility to recurrent aphthous stomatitis
BRPI0806599A2 (pt) Marcador e plataforma de diagnóstico para elaboração de fármaco em infarto do miocárdio e falência cardíaca
US9157119B2 (en) Methods for diagnosing skin diseases
EP1666611A1 (en) Diagnosis of arterial diseases by identification of a mutation in the MYH11 gene or protein
de Jong et al. No association between Annexin A5 genetic variants and deep venous thrombosis
US20150031569A1 (en) Mutations of the GPR179 Gene in Congenital Stationary Night Blindness
JP2011004619A (ja) 免疫疾患の検査方法、及び免疫疾患の予防又は治療薬のスクリーニング方法
WO2010009534A1 (en) Methods for the treatment, prevention and diagnosis of lipid metabolism associated diseases
CN114836534A (zh) Samd9l基因突变作为i型干扰素病诊断的标志物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120619

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130625

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5305921

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees